BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
GlobalData on MSN1d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
BridgeBio Pharma Inc. jumped in premarket trading after its drug got US regulators’ nod to treat a deadly form of heart ...
(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3 ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback